Dopamine D3 receptors as a therapeutic target for methamphetamine dependence

References

• Rawson RA, Condon TP. Why do we need an Addiction supplement focused on methamphetamine? Addiction 2007;102:1–4
   PubMed Web of Science ®Google Scholar
• Calcaterra S, Binswanger IA. National trends in psychostimulant-related deaths: 1999–2009. Subst Abus 2013;34:129–136
   PubMed Web of Science ®Google Scholar
• Nicosia N, Pacula RL, Kilmer B, Lundberg R, Chiesa J. The economic cost of methamphetamine use in the United States, 2005. Santa Monica, CA: RAND Corporation, 2009. http://www.rand.org/pubs/monographs/MG829
   Google Scholar
• Meredith CW, Jaffe C, Ang-Lee K, Saxon AJ. Implications of chronic methamphetamine use: a literature review. Harv Rev Psychiatry 2005;13:141–154
   PubMed Web of Science ®Google Scholar
• Brackins T, Brahm NC, Kissack JC. Treatments for methamphetamine abuse: a literature review for the clinician. J Pharm Pract 2011;24:541–550
   PubMedGoogle Scholar
• Vocci FJ, Appel NM. Approaches to the development of medications for the treatment of methamphetamine dependence. Addiction 2007;102:96–106
   PubMed Web of Science ®Google Scholar
• Newman AH, Blaylock BL, Nader MA, Bergman J, Sibley DR, Skolnick P. Medication discovery for addiction: translating the dopamine D3 receptor hypothesis. Biochem Pharmacol 2012;84:882–890
   PubMed Web of Science ®Google Scholar
• Boileau I, Payer D, Houle S, Behzadi A, Rusjan PM, Tong J, Wilkins D, et al. Higher binding of the dopamine D3 receptor-preferring ligand [11C]-(+)-propyl-hexahydro-naphtho-oxazin in methamphetamine polydrug users: a positron emission tomography study. J Neurosci 2012;32:1353–1359
   PubMed Web of Science ®Google Scholar
• Payer DE, Behzadi A, Kish SJ, Houle S, Wilson AA, Rusjan PM, Tong J, et al. Heightened D3 dopamine receptor levels in cocaine dependence and contributions to the addiction behavioural phenotype: a positron emission tomography study with [11C]-(+)-PHNO. Neuropsychopharmacology 2013 Aug 7. doi: 10.1038/npp.2013.192. [Epub ahead of print]
   Google Scholar
• Sokoloff P, Diaz J, Le Foll B, Guillin O, Leriche L, Bezard E, Gross C. The dopamine D3 receptor: a therapeutic target for the treatment of neuropsychiatric disorders. CNS Neurol Disord Drug Targets 2006;5:25–43
   PubMedGoogle Scholar
• Heidbreder CA, Newman AH. Current perspectives on selective dopamine D(3) receptor antagonists as pharmacotherapeutics for addictions and related disorders. Ann N Y Acad Sci 2010;1187:4–34
   PubMed Web of Science ®Google Scholar
• Eison AS, Eison MS, Stanley M, Riblet LA. Serotonergic mechanisms in the behavioral effects of buspirone and gepirone. Pharmacol Biochem Behav 1986;24:701–707
   PubMed Web of Science ®Google Scholar
• Schreiber R, De Vry J. Neuronal circuits involved in the anxiolytic effects of the 5-HT1A receptor agonists 8-OH-DPAT ipsapirone and buspirone in the rat. Eur J Pharmacol 1993;249:341–351
   PubMedGoogle Scholar
• Wong H, Dockens RC, Pajor L, Yeola S, Grace JE Jr, Stark AD, Taub RA, et al. 6-Hydroxybuspirone is a major active metabolite of buspirone: assessment of pharmacokinetics and 5-hydroxytryptamine1A receptor occupancy in rats. Drug Metab Dispos 2007;35:1387–1392
   PubMedGoogle Scholar
• Kula NS, Baldessarini RJ, Kebabian JW, Neumeyer JL. S-(+)-aporphines are not selective for human D3 dopamine receptors. Cell Mol Neurobiol 1994;14:185–191
   PubMedGoogle Scholar
• Tallman JF, Primus RJ, Brodbeck R, Cornfield L, Meade R, Woodruff K, Ross P, et al. I. NGD 94-1: identification of a novel, high-affinity antagonist at the human dopamine D4 receptor. J Pharmacol Exp Ther 1997;282:1011–1019
   PubMedGoogle Scholar
• Banala AK, Levy BA, Khatri SS, Furman CA, Roof RA, Mishra Y, Griffin SA, et al. N-(3-fluoro-4-(4-(2-methoxy or 2,3-dichlorophenyl)piperazine-1-yl)butyl)arylcarboxamides as selective dopamine D3 receptor ligands: critical role of the carboxamide linker for D3 receptor selectivity. J Med Chem 2011;54:3581–3594
   PubMedGoogle Scholar
• Young R, Bondareva T, Wesolowska A, Glennon RA. Modulation of a (+)amphetamine discriminative stimulus in rats by 8-hydroxy-2-(N,N-di-n-propylamino)tetralin (8-OH DPAT). Pharmacol Biochem Behav 2006;83:612–617
   PubMedGoogle Scholar
• Nader MA, Woolverton WL. Blockade of the discriminative stimulus effects of d-amphetamine in rhesus monkeys with serotonin 5-HT(1A) agonists. Behav Pharmacol 1994;5:591–598
   PubMedGoogle Scholar
• Munzar P, Laufert MD, Kutkat SW, Nováková J, Goldberg SR. Effects of various serotonin agonists, antagonists, and uptake inhibitors on the discriminative stimulus effects of methamphetamine in rats. J Pharmacol Exp Ther 1999;291:239–250
   PubMedGoogle Scholar
• Gold LH, Balster RL. Effects of buspirone and gepirone on i.v. cocaine self-administration in rhesus monkeys. Psychopharmacology (Berl) 1992;108:289–294
   PubMedGoogle Scholar
• Callahan PM, Cunningham KA. Modulation of the discriminative stimulus properties of cocaine: comparison of the effects of fluoxetine with 5-HT1A and 5-HT1B receptor agonists. Neuropharmacology 1997;36:373–381
   PubMedGoogle Scholar
• Yan Y, Pushparaj A, Le Strat Y, Gamaleddin I, Barnes C, Justinova Z, Goldberg SR, Le Foll B. Blockade of dopamine d4 receptors attenuates reinstatement of extinguished nicotine-seeking behavior in rats. Neuropsychopharmacology 2012;37:685–696
   PubMed Web of Science ®Google Scholar
• Bergman J, Roof RA, Furman CA, Conroy JL, Mello NK, Sibley DR, Skolnick P. Modification of cocaine self-administration by buspirone (buspar®): potential involvement of D3 and D4 dopamine receptors. Int J Neuropsychopharmacol 2013;16:445–458
   PubMed Web of Science ®Google Scholar
• Koob GF, Volkow ND. Neurocircuitry of addiction. Neuropsychopharmacology 2010;35:217–238
   PubMed Web of Science ®Google Scholar
• Sokoloff P, Giros B, Martres MP, Bouthenet ML, Schwartz JC. Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature 1990;347:146–151
   PubMed Web of Science ®Google Scholar
• Hall H, Halldin C, Dijkstra D, Wikström H, Wise LD, Pugsley TA, Sokoloff P, et al. Autoradiographic localisation of D3-dopamine receptors in the human brain using the selective D3-dopamine receptor agonist (+)-[3H]PD 128907. Psychopharmacology (Berl) 1996;128:240–247
   PubMedGoogle Scholar
• Tziortzi AC, Searle GE, Tzimopoulou S, Salinas C, Beaver JD, Jenkinson M, Laruelle M, et al. Imaging dopamine receptors in humans with [11C]-(+)-PHNO: dissection of D3 signal and anatomy. Neuroimage 2011;54:264–277
   PubMed Web of Science ®Google Scholar
• Liu XY, Mao LM, Zhang GC, Papasian CJ, Fibuch EE, Lan HX, Zhou HF, et al. Activity-dependent modulation of limbic dopamine D3 receptors by CaMKII. Neuron 2009;61:425–438
   PubMed Web of Science ®Google Scholar
• Sokoloff P, Leriche L, Diaz J, Louvel J, Pumain R. Direct and indirect interactions of the dopamine D3 receptor with glutamate pathways: implications for the treatment of schizophrenia. Naunyn Schmiedebergs Arch Pharmacol 2013;386:107–124
   PubMedGoogle Scholar
• Joyce JN, Millan MJ. Dopamine D3 receptor agonists for protection and repair in Parkinson’s disease. Curr Opin Pharmacol 2007;7:100–105
   PubMed Web of Science ®Google Scholar
• Boileau I, Guttman M, Rusjan P, Adams JR, Houle S, Tong J, Hornykiewicz O, et al. Decreased binding of the D3 dopamine receptor-preferring ligand [11C]-(+)-PHNO in drug-naive Parkinson’s disease. Brain 2009;132:1366–1375
   PubMedGoogle Scholar
• Gross G, Wicke K, Drescher KU. Dopamine D3 receptor antagonism – still a therapeutic option for the treatment of schizophrenia. Naunyn Schmiedeberg’s Arch Pharmacol 2013;386:155–166
   Google Scholar
• Schwendt M, Rocha A, See RE, Pacchioni AM, McGinty JF, Kalivas PW. Extended methamphetamine self-administration in rats results in a selective reduction of dopamine transporter levels in the prefrontal cortex and dorsal striatum not accompanied by marked monoaminergic depletion. J Pharmacol Exp Ther 2009;331:555–562
   PubMedGoogle Scholar
• Laćan G, Hadamitzky M, Kuczenski R, Melega WP. Alterations in the striatal dopamine system during intravenous methamphetamine exposure: effects of contingent and noncontingent administration. Synapse 2013;67:476--488
   Google Scholar
• Segal DS, Kuczenski R, O’Neil ML, Melega WP, Cho AK. Prolonged exposure of rats to intravenous methamphetamine: behavioral and neurochemical characterization. Psychopharmacology (Berl) 2005;180:501–512
   PubMedGoogle Scholar
• Stefanski R, Lee SH, Yasar S, Cadet JL, Goldberg SR. Lack of persistent changes in the dopaminergic system of rats withdrawn from methamphetamine self-administration. Eur J Pharmacol 2002;439:59–68
   PubMedGoogle Scholar
• Richtand NM, Welge JA, Levant B, Logue AD, Hayes S, Pritchard LM, Geracioti TD, et al. Altered behavioral response to dopamine D3 receptor agonists 7-OH-DPAT and PD 128907 following repetitive amphetamine administration. Neuropsychopharmacology 2003;28:1422–1432
   PubMedGoogle Scholar
• Chiang YC, Chen PC, Chen JC. D(3) dopamine receptors are down-regulated in amphetamine sensitized rats and their putative antagonists modulate the locomotor sensitization to amphetamine. Brain Res 2003;972:159–167
   PubMedGoogle Scholar
• Chen PC, Lao CL, Chen JC. Dual alteration of limbic dopamine D1 receptor-mediated signalling and the Akt/GSK3 pathway in dopamine D3 receptor mutants during the development of methamphetamine sensitization. J Neurochem 2007;100:225–241
   PubMedGoogle Scholar
• Bordet R, Ridray S, Carboni S, Diaz J, Sokoloff P, Schwartz JC. Induction of dopamine D3 receptor expression as a mechanism of behavioral sensitization to levodopa. Proc Natl Acad Sci 1997;94:3363–3367
   PubMed Web of Science ®Google Scholar
• Bordet R, Ridray S, Schwartz JC, Sokoloff P. Involvement of the direct striatonigral pathway in levodopa-induced sensitization in 6-hydroxydopamine-lesioned rats. Eur J Neurosci 2000;12:2117–2123
   PubMed Web of Science ®Google Scholar
• Guillin O, Diaz J, Carroll P, Griffon N, Schwartz JC, Sokoloff P. BDNF controls dopamine D3 receptor expression and triggers behavioural sensitization. Nature 2001;411:86–89
   PubMed Web of Science ®Google Scholar
• Le Foll B, Schwartz JC, Sokoloff P. Disruption of nicotine conditioning by dopamine D(3) receptor ligands. Mol Psychiatry 2003;8:225–230
   PubMed Web of Science ®Google Scholar
• Zhu J, Chen Y, Zhao N, Cao G, Dang Y, Han W, Xu M, Chen T. Distinct roles of dopamine D3 receptors in modulating methamphetamine-induced behavioral sensitization and ultrastructural plasticity in the shell of the nucleus accumbens. J Neurosci Res 2012;90:895–904
   PubMedGoogle Scholar
• Staley JK, Mash DC. Adaptive increase in D3 dopamine receptors in the brain reward circuits of human cocaine fatalities. J Neurosci 1996;16:6100–6106
   PubMed Web of Science ®Google Scholar
• Segal DM, Moraes CT, Mash DC. Up-regulation of D3 dopamine receptor mRNA in the nucleus accumbens of human cocaine fatalities. Brain Res Mol Brain Res 1997;45:335–339
   PubMedGoogle Scholar
• Volkow ND, Chang L, Wang GJ, Fowler JS, Ding YS, Sedler M, Logan J, et al. Low level of brain dopamine D2 receptors in methamphetamine abusers: association with metabolism in the orbitofrontal cortex. Am J Psychiatry 2001;158:2015–2021
   PubMed Web of Science ®Google Scholar
• Lee B, London ED, Poldrack RA, Farahi J, Nacca A, Monterosso JR, Mumford JA, et al. Striatal dopamine d2/d3 receptor availability is reduced in methamphetamine dependence and is linked to impulsivity. J Neurosci 2009;29:14734–14740
   PubMed Web of Science ®Google Scholar
• McCann UD, Wong DF, Yokoi F, Villemagne V, Dannals RF, Ricaurte GA. Reduced striatal dopamine transporter density in abstinent methamphetamine and methcathinone users: evidence from positron emission tomography studies with [11C]WIN-35,428. J Neurosci 1998;18:8417–8422
   PubMed Web of Science ®Google Scholar
• Kitamura O. Detection of methamphetamine neurotoxicity in forensic autopsy cases. Leg Med (Tokyo) 2009;11:S63–65
   PubMedGoogle Scholar
• Cadet JL, Krasnova IN, Jayanthi S, Lyles J. Neurotoxicity of substituted amphetamines: molecular and cellular mechanisms. Neurotox Res 2007;11:183–202
   PubMed Web of Science ®Google Scholar
• Wang GJ, Smith L, Volkow ND, Telang F, Logan J, Tomasi D, Wong CT, et al. Decreased dopamine activity predicts relapse in methamphetamine abusers. Mol Psychiatry 2012;17:918–925
   PubMed Web of Science ®Google Scholar
• Martinez D, Carpenter KM, Liu F, Slifstein M, Broft A, Friedman AC, Kumar D, et al. Imaging dopamine transmission in cocaine dependence: link between neurochemistry and response to treatment. Am J Psychiatry 2011;168:634–641
   PubMed Web of Science ®Google Scholar
• Spiller K, Xi ZX, Peng XQ, Newman AH, Ashby CR Jr, Heidbreder C, Gaál J, Gardner EL. The selective dopamine D3 receptor antagonists SB-277011A and NGB 2904 and the putative partial D3 receptor agonist BP-897 attenuate methamphetamine-enhanced brain stimulation reward in rats. Psychopharmacology (Berl) 2008;196:533–542
   PubMed Web of Science ®Google Scholar
• Higley AE, Spiller K, Grundt P, Newman AH, Kiefer SW, Xi ZX, Gardner EL. PG01037, a novel dopamine D3 receptor antagonist, inhibits the effects of methamphetamine in rats. J Psychopharmacol 2011;25:263–273
   PubMedGoogle Scholar
• Newman AH, Grundt P, Nader MA. Dopamine D3 receptor partial agonists and antagonists as potential drug abuse therapeutic agents. J Med Chem 2005;48:3663–3679
   PubMed Web of Science ®Google Scholar
• Higley AE, Kiefer SW, Li X, Gaál J, Xi ZX, Gardner EL. Dopamine D(3) receptor antagonist SB-277011A inhibits methamphetamine self-administration and methamphetamine-induced reinstatement of drug-seeking in rats. Eur J Pharmacol 2011;659:187–192
   PubMedGoogle Scholar
• Orio L, Wee S, Newman AH, Pulvirenti L, Koob GF. The dopamine D3 receptor partial agonist CJB090 and antagonist PG01037 decrease progressive ratio responding for methamphetamine in rats with extended-access. Addict Biol 2010;15:312–323
   PubMedGoogle Scholar
• Arnold JM, Roberts DC. A critique of fixed and progressive ratio schedules used to examine the neural substrates of drug reinforcement. Pharmacol Biochem Behav 1997;57:441–447
   PubMedGoogle Scholar
• Richardson NR, Roberts DC. Progressive ratio schedules in drug self-administration studies in rats: a method to evaluate reinforcing efficacy. J Neurosci Methods 1996;66:1–11
   PubMed Web of Science ®Google Scholar
• Shelton KL, Hendrick ES, Beardsley PM. Efficacy of buspirone for attenuating cocaine and methamphetamine reinstatement in rats. Drug Alcohol Depend 2013;129:210–216
   PubMed Web of Science ®Google Scholar
• Ashby CR Jr, Paul M, Gardner EL, Heidbreder CA, Hagan JJ. Acute administration of the selective D3 receptor antagonist SB-277011A blocks the acquisition and expression of the conditioned place preference response to heroin in male rats. Synapse 2003;48:154–156
   PubMed Web of Science ®Google Scholar
• Heidbreder CA, Andreoli M, Marcon C, Hutcheson DM, Gardner EL, Ashby CR Jr. Evidence for the role of dopamine D3 receptors in oral operant alcohol self-administration and reinstatement of alcohol-seeking behavior in mice. Addict Biol 2007;12:35–50
   PubMed Web of Science ®Google Scholar
• Xi ZX, Gilbert JG, Pak AC, Ashby CR Jr, Heidbreder CA, Gardner EL. Selective dopamine D3 receptor antagonism by SB-277011A attenuates cocaine reinforcement as assessed by progressive-ratio and variable-cost-variable-payoff fixed-ratio cocaine self-administration in rats. Eur J Neurosci 2005;21:3427–3438
   PubMed Web of Science ®Google Scholar
• Xi ZX, Newman AH, Gilbert JG, Pak AC, Peng XQ, Ashby CR Jr, Gitajn L, Gardner EL. The novel dopamine D3 receptor antagonist NGB 2904 inhibits cocaine’s rewarding effects and cocaine-induced reinstatement of drug-seeking behavior in rats. Neuropsychopharmacology 2006;31:1393–1405
   PubMed Web of Science ®Google Scholar
• Song R, Yang RF, Wu N, Su RB, Li J, Peng XQ, Li X, et al. YQA14: a novel dopamine D3 receptor antagonist that inhibits cocaine self-administration in rats and mice, but not in D3 receptor-knockout mice. Addict Biol 2012;17:259–273
   PubMed Web of Science ®Google Scholar
• Vorel SR, Ashby CR Jr, Paul M, Liu X, Hayes R, Hagan JJ, Middlemiss DN, et al. Dopamine D3 receptor antagonism inhibits cocaine-seeking and cocaine-enhanced brain reward in rats. J Neurosci 2002;22:9595–9603
   PubMed Web of Science ®Google Scholar
• Peng XQ, Ashby CR Jr, Spiller K, Li X, Li J, Thomasson N, Millan MJ, et al. The preferential dopamine D3 receptor antagonist S33138 inhibits cocaine reward and cocaine-triggered relapse to drug-seeking behavior in rats. Neuropharmacology 2009;56:752–760
   PubMedGoogle Scholar
• Xi ZX, Gilbert J, Campos AC, Kline N, Ashby CR Jr, Hagan JJ, Heidbreder CA, Gardner EL. Blockade of mesolimbic dopamine D3 receptors inhibits stress-induced reinstatement of cocaine-seeking in rats. Psychopharmacology (Berl) 2004;176:57–65
   PubMed Web of Science ®Google Scholar
• Achat-Mendes C, Grundt P, Cao J, Platt DM, Newman AH, Spealman RD. Dopamine D3 and D2 receptor mechanisms in the abuse-related behavioral effects of cocaine: studies with preferential antagonists in squirrel monkeys. J Pharmacol Exp Ther 2010;334:556–565
   PubMedGoogle Scholar
• Gilbert JG, Newman AH, Gardner EL, Ashby CR Jr, Heidbreder CA, Pak AC, Peng XQ, Xi ZX. Acute administration of SB-277011A, NGB 2904, or BP 897 inhibits cocaine cue-induced reinstatement of drug-seeking behavior in rats: role of dopamine D3 receptors. Synapse 2005;57:17–28
   PubMed Web of Science ®Google Scholar
• Gál K, Gyertyán I. Dopamine D3 as well as D2 receptor ligands attenuate the cue-induced cocaine-seeking in a relapse model in rats. Drug Alcohol Depend 2006;81:63–70
   PubMedGoogle Scholar
• Cervo L, Cocco A, Petrella C, Heidbreder CA. Selective antagonism at dopamine D3 receptors attenuates cocaine-seeking behaviour in the rat. Int J Neuropsychopharmacol 2007;10:167–181
   PubMed Web of Science ®Google Scholar
• Mello NK, Fivel PA, Kohut SJ, Bergman J. Effects of chronic buspirone treatment on cocaine self-administration. Neuropsychopharmacology 2013;38:455–467
   PubMed Web of Science ®Google Scholar
• Mello NK, Fivel PA, Kohut SJ. Effects of chronic buspirone treatment on nicotine and concurrent nicotine+cocaine self-administration. Neuropsychopharmacology 2013;38:1264--1275
   Google Scholar
• Andreoli M, Tessari M, Pilla M, Valerio E, Hagan JJ, Heidbreder CA. Selective antagonism at dopamine D3 receptors prevents nicotine-triggered relapse to nicotine-seeking behavior. Neuropsychopharmacology 2003;28:1272–1280
   PubMed Web of Science ®Google Scholar
• Le Foll B, Sokoloff P, Stark H, Goldberg SR. Dopamine D3 receptor ligands block nicotine-induced conditioned place preferences through a mechanism that does not involve discriminative-stimulus or antidepressant-like effects. Neuropsychopharmacology 2005;30:720–730
   PubMed Web of Science ®Google Scholar
• Pak AC, Ashby CR Jr, Heidbreder CA, Pilla M, Gilbert J, Xi ZX, Gardner EL. The selective dopamine D3 receptor antagonist SB-277011A reduces nicotine-enhanced brain reward and nicotine-paired environmental cue functions. Int J Neuropsychopharmacol 2006;9:585–602
   PubMed Web of Science ®Google Scholar
• Ross JT, Corrigall WA, Heidbreder CA, LeSage MG. Effects of the selective dopamine D3 receptor antagonist SB-277011A on the reinforcing effects of nicotine as measured by a progressive-ratio schedule in rats. Eur J Pharmacol 2007;559:173–179
   PubMed Web of Science ®Google Scholar
• Khaled MA, Farid Araki K, Li B, Coen KM, Marinelli PW, Varga J, Gaál J, Le Foll B. The selective dopamine D3 receptor antagonist SB 277011-A, but not the partial agonist BP 897, blocks cue-induced reinstatement of nicotine-seeking. Int J Neuropsychopharmacol 2010;13:181–190
   PubMed Web of Science ®Google Scholar
• Micheli F, Arista L, Bonanomi G, Blaney FE, Braggio S, Capelli AM, Checchia A, et al. 1,2,4-Triazolyl azabicyclo[3.1.0]hexanes: a new series of potent and selective dopamine D(3) receptor antagonists. J Med Chem 2010;53:374–391
   PubMedGoogle Scholar
• Mugnaini M, Iavarone L, Cavallini P, Griffante C, Oliosi B, Savoia C, Beaver J, et al. Occupancy of brain dopamine D3 receptors and drug craving: a translational approach. Neuropsychopharmacology 2013;38:302–312
   PubMed Web of Science ®Google Scholar
• Nathan PJ, O’Neill BV, Mogg K, Bradley BP, Beaver J, Bani M, Merlo-Pich E, et al. The effects of the dopamine D3 receptor antagonist GSK598809 on attentional bias to palatable food cues in overweight and obese subjects. Int J Neuropsychopharmacol 2012;15:149–161
   PubMedGoogle Scholar
• Winhusen T, Brady KT, Stitzer M, Woody G, Lindblad R, Kropp F, Brigham G, et al. Evaluation of buspirone for relapse-prevention in adults with cocaine dependence: an efficacy trial conducted in the real world. Contemp Clin Trials 2012;33:993–1002
   PubMed Web of Science ®Google Scholar
• Giannini AJ, Loiselle RH, Graham BH, Folts DJ. Behavioral response to buspirone in cocaine and phencyclidine withdrawal. J Subst Abuse Treat 1993;10:523–527
   PubMed Web of Science ®Google Scholar
• Moeller FG, Dougherty DM, Barratt ES, Schmitz JM, Swann AC, Grabowski J. The impact of impulsivity on cocaine use and retention in treatment. J Subst Abuse Treat 2001;21:193–198
   PubMed Web of Science ®Google Scholar
• Malec TS, Malec EA, Dongier M. Efficacy of buspirone in alcohol dependence: a review. Alcohol Clin Exp Res 1996;20:853–858
   PubMed Web of Science ®Google Scholar
• Fawcett J, Kravitz HM, McGuire M, Easton M, Ross J, Pisani V, Fogg LF, et al. Pharmacological treatments for alcoholism: revisiting lithium and considering buspirone. Alcohol Clin Exp Res 2000;24:666–674
   PubMedGoogle Scholar
• McRae AL, Brady KT, Carter RE. Buspirone for treatment of marijuana dependence: a pilot study. Am J Addict 2006;15:404
   PubMed Web of Science ®Google Scholar
• McRae-Clark AL, Carter RE, Killeen TK, Carpenter MJ, Wahlquist AE, Simpson SA, Brady KT. A placebo-controlled trial of buspirone for the treatment of marijuana dependence. Drug Alcohol Depend 2009;105:132–138
   PubMedGoogle Scholar
• Buydens-Branchey L, Branchey M, Reel-Brander C. Efficacy of buspirone in the treatment of opioid withdrawal. J Clin Psychopharmacol 2005;25:230–236
   PubMedGoogle Scholar
• Cinciripini PM, Lapitsky L, Seay S, Wallfisch A, Meyer WJ 3rd, van Vunakis H. A placebo-controlled evaluation of the effects of buspirone on smoking cessation: differences between high- and low-anxiety smokers. J Clin Psychopharmacol 1995;15:182–191
   PubMed Web of Science ®Google Scholar
• Schneider NG, Olmstead RE, Steinberg C, Sloan K, Daims RM, Brown HV. Efficacy of buspirone in smoking cessation: a placebo-controlled trial. Clin Pharmacol Ther 1996;60:568–575
   PubMed Web of Science ®Google Scholar
• Jasinski DR, Nutt JG, Haertzen CA, Griffith JD, Bunney WE. Lithium: effects on subjective functioning and morphine-induced euphoria. Science 1977;195:582–584
   PubMed Web of Science ®Google Scholar
• Martin WR, Sloan JW, Sapira JD, Jasinski DR. Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man. Clin Pharmacol Ther 1971;12:245–258
   PubMed Web of Science ®Google Scholar
• Rush CR, Stoops WW, Hays LR, Glaser PE, Hays LS. Risperidone attenuates the discriminative-stimulus effects of d-amphetamine in humans. J Pharmacol Exp Ther 2003;306:195–204
   PubMed Web of Science ®Google Scholar
• Oliveto AH, Bickel WK, Hughes JR, Shea PJ, Higgins ST, Fenwick JW. Caffeine drug discrimination in humans: acquisition, specificity and correlation with self-reports. J Pharmacol Exp Ther 1992;261:885–894
   PubMed Web of Science ®Google Scholar
• De La Garza R 2nd, Zorick T, London ED, Newton TF. Evaluation of modafinil effects on cardiovascular, subjective, and reinforcing effects of methamphetamine in methamphetamine-dependent volunteers. Drug Alcohol Depend 2010;106:173–180. doi: 10.1016/j.drugalcdep.2009.08.013
   PubMed Web of Science ®Google Scholar
• Newton TF, Reid MS, De La Garza R, Mahoney JJ, Abad A, Condos R, Palamar J, et al. Evaluation of subjective effects of aripiprazole and methamphetamine in methamphetamine-dependent volunteers. Int J Neuropsychopharmacol 2008;11:1037–1045
   PubMed Web of Science ®Google Scholar
• Sevak RJ, Stoops WW, Hays LR, Rush CR. Discriminative stimulus and subject-rated effects of methamphetamine, d-amphetamine, methylphenidate, and triazolam in methamphetamine-trained humans. J Pharmacol Exp Ther 2009;328:1007–1018
   PubMed Web of Science ®Google Scholar
• Mogg K, Bradley BP, O’Neill B, Bani M, Merlo-Pich E, Koch A, Bullmore ET, Nathan PJ. Effect of dopamine D3 receptor antagonism on approach responses to food cues in overweight and obese individuals. Behav Pharmacol 2012;23:603–608
   PubMed Web of Science ®Google Scholar
• Dodds CM, O’Neill B, Beaver J, Makwana A, Bani M, Merlo-Pich E, Fletcher PC, et al. Effect of the dopamine D3 receptor antagonist GSK598809 on brain responses to rewarding food images in overweight and obese binge eaters. Appetite 2012;59:27–33
   PubMedGoogle Scholar